Middleton, WI 11/29/16—Life science supplier Lucigen has announced that it will exclusively manufacture and sell certain Epicentre Technologies products, starting January 1, 2017. Epicentre is an Illumina subsidiary. Lucigen will offer Epicentre products for transposomics, microarray analysis and transcriptomics. “We are excited to expand and enrich our product offering to serve scientists worldwide with unique tools that will deliver innovative and meaningful breakthroughs in life sciences,” commented Lucigen CEO Ralph Kauten.

Illumina acquired Epicentre Biotechnologies in 2011 (see IBO 1/15/11), primarily for its Nextera NGS library preparation technology. As such, Epicentre’s other products  may not have been considered core to Illumina’s business, especially as it makes operational changes under a new CEO.